NON-SMALL CELL LUNG CANCER

This early-stage trial tests a new vaccine called IMP3-saRNA (YMN-136) for people with advanced non-small cell lung cancer who have run out of standard options. The vaccine uses self-amplifying RNA to train the immune system to attack cancer cells. Only 9 participants will be enr…

This study tests whether adding a precise, high-dose radiation treatment to the liver (called L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either stand…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified to produce a protein (IL15) t…

This study tests a new drug called CKD-703 for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. CKD-703 is designed to deliver a powerful chemotherapy drug directly to cancer cells that have a s…

This study tests whether combining ivonescimab with either Dato-DXd or osimertinib is safe and works for people with advanced EGFR-mutant non-small cell lung cancer that stopped responding to previous treatments. About 66 adults will join to find the best dose and check if tumors…

This study tests whether a new triple therapy—spatially fractionated radiotherapy (SFRT), the immunotherapy drug tislelizumab, and standard chemotherapy—can shrink initially unresectable stage 3 non-small cell lung cancer enough to allow surgery. About 30 participants will receiv…

This study tests a new drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 764 participants will receive th…

This early-stage study tests a new drug called tolododekin alfa combined with an immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. About 60 participants will join, including those wh…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if adding STK-012 helps shrink tumors better than standa…

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

This early-stage study tests a new radioactive drug that seeks out a protein called Nectin-4 on cancer cells. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The main goals are to find a saf…

This study tests whether the drug anlotinib can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take anlotinib capsules. The main goal is to see ho…

This study tests a new drug, SAR445877, in 29 adults with advanced non-small cell lung cancer that got worse after standard immunotherapy. The goal is to see if the drug can help control the cancer and to check for side effects. Participants must have tried all available treatmen…

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 420 adults will take part, and the study wi…

This study tests a treatment that uses immune cells taken from a patient's own lung tumor. These cells are grown in large numbers and then put back into the patient to attack the cancer. The goal is to see if this approach can stop or slow the cancer from growing in 30 adults wit…

This study tests a new drug (GEN-725) combined with dositinib in 110 adults with advanced EGFR-mutant non-small cell lung cancer that cannot be surgically removed. The goal is to see if the combination is safe and shrinks tumors. This is not a cure; it aims to control the disease…

This study tests whether adding the experimental drug MK-1084 to the standard immunotherapy pembrolizumab helps people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, adv…

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This study looks at whether adding surgery or radiation to the main lung tumor helps people with advanced EGFR-mutant lung cancer who already responded to initial treatment with osimertinib plus chemotherapy. About 70 adults will receive local therapy and be followed to see how l…

This study tests a lower dose of the targeted drug osimertinib in 58 adults with advanced EGFR-positive non-small cell lung cancer. The goal is to see if the lower dose is safer while still controlling the disease. Participants take the drug every other day, and researchers monit…

This study tests several targeted therapies and immunotherapies given before and after surgery for people with early-stage non-small cell lung cancer (stages IB to III). Participants are selected based on specific biomarkers in their tumors. The goal is to see if these treatments…

This early-phase study tests a new treatment for advanced lung cancer that uses a person's own immune cells, modified to better recognize and attack cancer cells. The treatment, called iC9-GD2.CAR.IL-15 T cells, combines antibodies and T cells to target a protein (GD2) found on s…

This study is for people with a specific type of lung cancer (EGFR-mutated) that can be removed with surgery. It tests whether giving a new drug, sacituzumab tirumotecan, alone or with another drug (osimertinib) before surgery can shrink the tumor more effectively. About 60 adult…

This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has worsened on previous treatments will receive the combination. Th…

This study tests two experimental drugs, DZD9008 and AZD4205, taken together for advanced non-small cell lung cancer with EGFR mutations that has worsened after standard treatments. About 90 adults will participate to see if the combination is safe and shrinks tumors. The goal is…

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This study tests a new drug called dositinib in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to find a safe dose and see if it shrinks tumors. About 153 adults aged 18-75 who have already tried other treatments wi…

This study tests whether adding a targeted drug (MK-1084) to standard immunotherapy after surgery can prevent lung cancer from returning in people with a specific KRAS gene mutation. About 400 adults with stage IIA-IIIB non-small cell lung cancer that has been fully removed will …

This phase 2 trial tests TQB2102, a drug that delivers a powerful toxin directly to cancer cells with a HER2 gene change. It aims to shrink or control tumors in 270 adults with advanced non-small cell lung cancer that cannot be surgically removed. Participants must have tried pri…

This program offers the experimental drug neladalkib to adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. The goal is to provide access to a promising th…

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells th…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from returning after surgery. About 868 people with stage II to IIIB non-small cell lung cancer who have had their tumor completely removed…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and shrinks tumors. About 320 adults who have not had prior treatment…

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who had a good long-term response to initial immunotherapy but still have cancer DNA in their blood. About 70 participants will be randomly a…

This study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. Researchers will first find a dose that causes few side effects, then see if that dose helps control the cancer. U…

This early-stage trial tests an experimental drug, MRTX1719, in adults with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants wit…

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for people who have had surgery for lung cancer, melanoma, or kidney cancer. The study will compare how the drugs move through the body, their safety, and how well they work.…

This study tests whether a targeted antibody-drug combo (trastuzumab deruxtecan) plus immunotherapy (pembrolizumab) works better than standard chemo plus immunotherapy for people with advanced non-small cell lung cancer that has high HER2 levels and low PD-L1. About 686 adults wh…

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …

This study tests a new combination of two drugs, DZD6008 and sunvozertinib, in adults with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to see if the combination is safe and can shrink tumors. About 200 people will take part in this early-phase…

This study tests a new way to perform lung cancer surgery for people with early-stage non-small cell lung cancer. Surgeons will use a 3D computer model (Synapse 3D) and a special dye (ICG) to see exactly which part of the lung needs to be removed. The goal is to remove only the d…

This early-stage study tests a new drug called SIM0610 in about 260 adults with advanced solid tumors (e.g., lung, colorectal, head and neck, liver cancer) that have spread. The main goals are to check the drug's safety and find the right dose, while also looking for signs that i…

This study tests whether a new drug called rilvegostomig, combined with standard chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced squamous non-small cell lung cancer that has spread. The trial involves about 880 pa…

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check safety …

This study is for people with stage IIB or III non-small cell lung cancer who cannot have surgery or standard chemo-radiation. It tests adding drugs that block DNA repair to standard radiation therapy, followed by a year of immunotherapy. The main goal is to find the safest dose …

This study tests a new oral drug, TNG456, in people with advanced solid tumors that have lost a gene called MTAP. The drug works by blocking a protein (PRMT5) that these tumors need to grow. The study has two parts: first, finding the safest dose of TNG456 alone or with abemacicl…

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard targeted therapy. About 40 adults will receive the combination to …

This early-phase study tests a new drug called GNC-077 in about 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must …

This study tests whether a personalized cancer vaccine (intismeran) alone or combined with an immunotherapy (pembrolizumab) can prevent non-small cell lung cancer from returning after surgery. About 876 adults with high-risk stage I lung cancer that was fully removed will be rand…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer DNA (ctDNA) remains detectable in the blood after a few weeks on the drug osimertinib alone. Those patients tend to do worse, so researchers want to see if adding a second drug (sacituzuma…

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a high level of a protein called c-Met. About 150 participants will receive one of three different doses of the drug to …

This phase 3 study tests whether adding SHR-A2009 to aumolertinib works better than aumolertinib alone for people with advanced EGFR-mutant non-small cell lung cancer who haven't had treatment yet. About 576 adults aged 18-75 will join. The main goal is to see if the combo delays…

This program provides early access to the investigational drug zidesamtinib for people with advanced ROS1-positive lung cancer or other solid tumors who have run out of standard options. Participants must have tried at least one prior ROS1-targeted therapy and cannot join a forma…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment for advanced disease will take part. The goal is to see if …

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer whose disease worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and helps shrink tumors. Th…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This study is testing whether combining an immunotherapy drug (atezolizumab), an immune-boosting agent (BDB001), and targeted radiation can help control advanced solid tumors. It includes people with pancreatic cancer, lung cancer, melanoma, bladder cancer, triple-negative breast…

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that attacks cancer cells, followed by standard chemotherapy plus an immunotherapy drug, and compares it to standard chem…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study tests a treatment plan for veterans with stage III non-small cell lung cancer that cannot be removed by surgery. Participants will receive chemotherapy and immunotherapy together, followed by radiation therapy. The goal is to see if this combination is safe and helps k…

This study tests a drug called zanidatamab in adults with certain advanced cancers (lung, endometrial, colorectal, head & neck, or sarcoma) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every 3 …

This study compares two treatments for people with metastatic non-small cell lung cancer who have not had prior therapy. One group receives the experimental drug ivonescimab plus chemotherapy, while the other receives the standard drug pembrolizumab plus chemotherapy. The trial a…

This study tests a drug called sunvozertinib in people with advanced non-small cell lung cancer who have not had prior treatment and carry certain uncommon EGFR gene mutations. About 34 participants will receive the drug to see how well it shrinks tumors and how safe it is. The g…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests a combination of two drugs—tulmimetostat and pembrolizumab—in people with advanced non-small cell lung cancer whose cancer has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. About 66 veterans will …

This early-phase study tests a new drug called PT0511 in about 195 adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works …

This study tests whether adding a special type of radiation (SFRT) to standard treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults with up to 5 progressing tumors will receive SFRT on those spots while contin…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…

This study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The main goal is to see how many patients' tumors shrink or …

This early-phase study tests a new treatment called PeptiCRAd-1, a virus-based cancer vaccine, combined with the immunotherapy drug pembrolizumab. The goal is to see if this combination is safe and can boost the immune system to fight several types of solid tumors, including mela…

This study tests the drug fingolimod (currently used for multiple sclerosis) in people with advanced non-small cell or small cell lung cancer whose cancer has worsened after standard treatments. The goal is to see if the drug is safe and can shrink tumors or slow cancer growth. A…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced solid tumors, including lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults who have not responded to other treatments will ta…

This study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck, or skin can…

This study tests whether giving low-dose radiation and immunotherapy before standard chemotherapy can help shrink tumors in people with stage II to III non-small cell lung cancer. The goal is to make surgery more effective and improve long-term outcomes. About 30 adults who have …

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This early-stage study tests an experimental drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 340 adults whose cancer ha…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This early-phase study is testing whether giving a short course of high-dose radiation before standard chemotherapy and immunotherapy can help shrink borderline resectable non-small cell lung cancer enough to allow successful surgery. About 18 adults with stage II to IIIC lung ca…

This study is for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has gotten worse after first-line treatment with a third-generation EGFR-TKI drug. The trial will test whether taking a higher dose of the drug furmonertinib, either alo…

This study tests whether adding a freezing treatment (cryoablation) to an immunotherapy drug (toripalimab) can help control advanced non-small cell lung cancer that has started to grow again after initial treatment. About 54 adults with a specific type of lung cancer will receive…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed with surgery. The goal is to see if the combination works better than standard care at shrinking tumors before surgery and preventing cance…

This study is for adults with advanced solid tumors that have a specific genetic change called STK11 mutation. The goal is to test a new drug, TNG260, given alone or with an immunotherapy drug (pembrolizumab). Researchers want to find the best dose, check safety, and see if the c…

This study tests whether a new drug called telisotuzumab vedotin works better than a standard chemotherapy (docetaxel) for adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will be …

This study tests a combination of three treatments (a targeted drug, chemotherapy into the spine, and precise radiation) as a first treatment for people with a specific type of lung cancer that has spread to the brain and its lining. About 30 adults with EGFR-mutated lung cancer …

This study is testing a drug called iruplinalkib in people with advanced ALK-positive lung cancer who have already tried and stopped responding to lorlatinib. Researchers want to see if iruplinalkib can help control the cancer and how safe it is. About 20 adults will take part, a…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that have lost a specific marker on their cells. The treatment uses the patient's own immune cells, modified to target cancer cells while protecti…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. Participants receive specially designed natural killer (NK) immune cells that target two cancer-related proteins on their tumor cells. The goal is to…

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The mai…

This study tests several new drug combinations given before and after surgery for people with early-stage non-small cell lung cancer. The goal is to see if these combinations can completely eliminate the cancer in the removed tissue and prevent it from coming back. About 630 adul…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study tests whether adding SKB264 to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer getting worse. About 420 adults who have not had prior treatment for advanced disease will be randomly assigned to receive e…

This study tests whether adding the antidepressant olanzapine to standard immunotherapy can help people with advanced non-small cell lung cancer live longer. About 156 adults with a specific type of lung cancer (EGFR mutation-negative) will receive either immunotherapy alone or i…

This early-phase trial tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part.

This study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene changes. The main goals are to check the drug's safety and how well it shrinks tumors. About 140 adults will take part, and the drug is given by mouth.

This study tests whether a new targeted drug (divarasib) plus an immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not …

This study tests a new drug called BNT327 combined with chemotherapy and other agents in people who have not yet been treated for advanced non-small cell lung cancer. The trial will include about 1,260 participants across multiple sites worldwide. The goal is to see if the combin…

This study tests a new drug called nelmastobart combined with the chemotherapy docetaxel in people with advanced non-small cell lung cancer whose cancer has stopped responding to or cannot tolerate standard platinum-based chemo or immunotherapy. About 62 participants will receive…

This study tests a new oral drug, sutetinib maleate, in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. About 66 adults will take the drug and be monitored for response and s…

This study uses a sensitive blood test (ctDNA) to find tiny amounts of cancer left after standard treatment for early-stage non-small cell lung cancer. If the test is positive, participants receive the drug durvalumab to try to clear the remaining cancer cells and lower the chanc…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels live longer or delay cancer growth. About 714 participants will receive either the combo or p…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study looks at the best sequence of targeted drugs (EGFR-inhibitors) for people with advanced EGFR-mutated lung cancer that cannot be cured. About 200 participants will receive different drug orders to see which improves life quality, reduces side effects, and controls tumor…

This study compares two types of minimally invasive surgery for early-stage non-small cell lung cancer: robot-assisted (RATS) and video-assisted (VATS). About 1,124 patients will be randomly assigned to one of the two procedures. The main goal is to see which approach leads to be…

This study tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest and most effective dose. About 150 participants will take th…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the body to fight the cancer. The study w…

This study tests whether adding a traditional Chinese herbal decoction called HGXJT to standard immunotherapy can better control non-small cell lung cancer that has spread to the bones. About 82 adults with this type of cancer will receive either the herbal medicine or a placebo …

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive both treatments. The m…

This study tests whether adding the drug MK-2870 to standard pembrolizumab after initial chemo-immunotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive pembrolizumab plus chemotherapy, then either continue pembr…

This study tests an experimental drug, LY3962673, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called KRAS G12D. The goal is to find safe doses and see if the drug shrinks tumors, both alone and with other …

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has gotten worse after taking targeted pills called EGFR tyrosine kinase inhibitors. About 596 adults …

This early-phase study tests a new drug called 177Lu-RAD204, which is a radioactive antibody that seeks out and attaches to a protein (PD-L1) on cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like lung, breast, or skin cancer th…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent non-small cell lung cancer from returning after surgery. About 390 people with stage II-IIIA lung cancer who have not had chemotherapy will receive cemiplimab or be observed. The study focuses on patie…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether a transplant of healthy gut bacteria (from donor stool) combined with the immunotherapy drug pembrolizumab can help people with advanced lung cancer that has stopped responding to standard treatments. About 26 participants will receive the bacteria transp…

This study tests a new drug called QL1706 (a type of immunotherapy) combined with standard chemotherapy for people with a certain stage of non-small cell lung cancer that can be removed with surgery. About 30 participants will receive the drug combination before surgery to shrink…

This study tests a new type of radiation surgery called hypervision proton surgery for people with early-stage non-small cell lung cancer. The goal is to see if it is safe and can control the tumor using one or two high-dose treatments. About 12 participants will be followed for …

This study is testing a type of radiation called stereotactic body radiation therapy (SBRT) for people with lung cancer or cancer that has spread to the lung. The treatment delivers high doses of radiation in just 3 to 10 sessions over 1 to 2 weeks. Researchers want to see how we…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly diagnosed, unt…

This study tests whether giving high-precision radiation (SBRT) before chemotherapy can better control stage III non-small cell lung cancer. It involves 20 adults aged 18-75 with tumors smaller than 6 cm. The goal is to see if this approach improves local control and survival wit…

This study tests whether a new drug (SKB264) combined with pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks a protein called PD-L1. About 432 adults with stage IIIB/IV cancer who haven't had prio…

This study compares two drug combinations for people with advanced squamous non-small cell lung cancer who have not had treatment before. About 574 participants will receive either RC148 or tislelizumab, both combined with standard chemotherapy. The goal is to see which combinati…

This study tests an experimental drug called YL202 in about 100 adults with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if YL202 can shrink tumors. Participants will receive the drug …

This study tests a new two-drug combination (ZG005 and gecacitinib) in people with advanced non-small cell lung cancer that has not responded to standard PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. About 50 adults aged 18 to 75 will take …

This study tests two different dosing schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. The goal is to find the best dosing regimen for people with previously untreated metastatic or…

This study tests whether giving the drug trastuzumab deruxtecan before routine surgery can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated non-small cell lung cancer). About 14 adults with stage II to IIIB lung cancer will receive the d…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…

This study tests a new drug called volrustomig combined with other cancer medicines in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 180 adults will take part, and the study is currently recruiting.

This study tests whether adding targeted radiotherapy to the usual drug treatment can lower the chance of lung cancer growing or spreading. It involves 320 adults with stage IV non-small-cell lung cancer whose disease has started to progress in a limited number of spots while on …

This early-phase study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goal is to find the safest dose and check for side effects when given alone or with standard treatments. Participa…

This study tests whether giving radiation to the main lung tumor before starting targeted therapy (a pill called a TKI) can delay cancer growth in people with advanced non-small cell lung cancer that has a specific gene mutation. About 34 adults who have not yet been treated will…

This study tests a device that uses focused ultrasound to temporarily open the blood-brain barrier in people with brain metastases from non-small cell lung cancer. The goal is to see if this helps standard immunotherapy drugs work better against the brain tumors. About 30 adults …

This study tests a combination of a healthy gut bacteria (EXL01) and the immunotherapy drug nivolumab for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 21 participants will receive the combination to see if it can help c…

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous NSCLC) live longer without their cancer growing. About 300 adults who have not had prior treatment for their…

This phase 3 trial compares two immunotherapy combinations for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher. Participants receive either nivolumab plus relatlimab with chemotherapy or pembrolizumab with chemotherapy. The study aims …

This early-stage study tests a new drug called azirkitug, alone or with other medicines, in people with advanced solid tumors like lung, head/neck, and other cancers. The goal is to find safe doses and check side effects. About 694 adults will take part at sites worldwide.

This study tests whether adding a special surgical glue (Progel Platinum) to the standard stapling method during lung cancer surgery can help patients recover faster. About 160 adults having keyhole surgery for non-small cell lung cancer will take part. The main goal is to see if…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests whether adding AGuIX nanoparticles to precise, MRI-guided radiation therapy can better control centrally located lung tumors and advanced pancreatic cancer. About 100 adults with these cancers will receive the combination treatment. The goal is to find the safest…

This study tests a new drug called andamertinib, alone or with chemotherapy, for people with advanced lung cancer that has certain rare gene changes (atypical EGFR mutations). About 40 participants who have not had prior treatment will be randomly assigned to receive the drug, th…

This study tests whether giving the immunotherapy drug durvalumab after chemotherapy and surgery can help prevent lung cancer from coming back. About 290 adults with stage IIB-IIIB non-small cell lung cancer will receive durvalumab plus chemo before surgery, then either more durv…

This study tests whether adding a new drug, BL-B01D1, to the standard pill osimertinib helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer growing. About 720 adults with this type of lung cancer will be randomly assigned to receive …

This early-phase study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors like pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see if it …

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The goal is to find safe doses and see if the combination can shrink tumors. About 160 adults aged 18 to 75 are being enrolled.

This study is for people with a type of advanced lung cancer that lacks the PD-L1 marker. It compares standard treatment (one immunotherapy drug plus chemo) to a stronger approach (two immunotherapy drugs plus chemo). The goal is to see if the double therapy clears cancer DNA fro…

This study tests two new treatments for people with advanced non-squamous lung cancer that has high PD-L1 levels. One group gets a combination of two drugs (datopotamab deruxtecan and rilvegostomig), another gets rilvegostomig alone, and a third gets the standard drug pembrolizum…

This study tests whether adding a new drug (patritumab deruxtecan) to standard immunotherapy (pembrolizumab) with or without chemotherapy can better control advanced non-small cell lung cancer. About 90 people with untreated stage IV lung cancer will participate. The goal is to s…

This study is for people with stage IB to III non-small cell lung cancer that can be removed with surgery. Before surgery, participants receive a low dose of targeted radiation along with two immunotherapy drugs (ipilimumab and nivolumab). The goal is to see if this combination c…

This study tests a combination of SKB264 and KL-A167, with or without chemotherapy, in 110 adults with advanced non-small cell lung cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease, while checking for side effects. Participants must ha…

This early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…

This study tests a pill called cabozantinib in people with advanced non-small cell lung cancer that has certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug targets these changes to shrink tumors and stop them from growing. About 86 participants …

This study tests an experimental drug, telisotuzumab adizutecan, against standard care in about 430 adults with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after using a third-generation targeted therapy. The go…

This study tests whether combining three anti-cancer drugs (carboplatin, paclitaxel, and ramucirumab) can shrink tumors or slow their growth in people with advanced non-squamous non-small cell lung cancer. It includes about 59 adults whose cancer worsened after initial treatment …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left after lung cancer surgery. If the test shows cancer might come back, patients get extra treatment to try to stop it. The goal is to see if this approach can keep cancer away longer. About 66 peo…

This study tests a new surgical technique called septum-guided segmentectomy for people with small (≤2 cm), deep-seated early-stage lung cancer. Instead of removing an entire lung lobe, surgeons use natural lung boundaries to precisely remove only the diseased segment, aiming to …

This early-phase study tests a new drug called anvumetostat, alone or with other therapies, in adults with advanced chest tumors (like lung cancer) that have a specific genetic change (MTAP deletion). The main goals are to find the safest dose and check for side effects. About 50…

This study tests whether using a protein-based test to choose treatment can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard therapy …

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This early-phase trial tests a special immune cell treatment (CD40L TIL) combined with the drug nivolumab for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). The study aims to see if this approach is safe and can shrink t…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus low-dose liver radiation. The goa…

This study tests whether early, specialized heart monitoring and care can reduce heart complications in people with advanced lung cancer who are receiving chemotherapy, radiation, and immunotherapy. About 524 adults with stage III non-small cell lung cancer will be randomly assig…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. About 278 adults will receive different treatment mixes to see if they shrink tumors and are safe. The goal is to find better ways to control the disease and improve…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 414 adults aged 18-75 who have already tried …

This study looks at whether adding radiation therapy to standard immunotherapy after surgery can help keep non-small cell lung cancer from returning in patients with multiple lymph node metastases. About 60 adults aged 18 to 75 with stage III N2 lung cancer will be enrolled. The …

This study tests whether giving high-precision radiation (SBRT) to all visible tumors can delay cancer worsening in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will be randomly assigned to receive either standard care alone or standard care pl…

This early-phase study tests a new drug called PRTH-101, alone or with an approved immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if …

This study tests a new drug called KIVU-107 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to find the safest dose and check fo…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can better prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and i…

This study tests a treatment plan for people with stage III non-small cell lung cancer. First, patients receive three cycles of chemotherapy plus the immunotherapy drug atezolizumab. Then, depending on how well the tumor responds, they either have surgery followed by more atezoli…

This early-phase study tests a new oral drug, CGT4255, in about 100 adults whose advanced solid tumors have certain genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors, includi…

This study tests whether a combination of two experimental drugs (IN10018 and D-1553) works better than standard chemotherapy and immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 400 adults who have not had prior …

This study compares a new drug, taletrectinib, to the standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not had prior targeted therapy. About 194 participants will be randomly assigned to take eithe…

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects…

This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can shrink tumors in people with advanced solid tumors like lung, kidney, or liver cancer. About 170 adults whose cancer has worsened after standard treatments will receive the drug combination. The go…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from returning after surgery in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. About 400 adults who have had their tumor completely removed…

This early-phase study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't gotten worse after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are at high risk for surgery. One group will have a small surgery to remove the tumor, while the other will receive precise, high-dose radiation (SAbR). The goal is to see which approach…

This study looks at whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who have a lower performance status (ECOG 2). About 120 participants will receive either real…

This study is for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers want to see if adding another immunotherapy drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA found in t…

This study tests two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if the combination can shrink or eliminate tumors, making surgery more effective. About 60 adults with stage II-IIIB lung cancer will participate.

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have certain changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug called panitumumab. The study…

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The goal is to see if the treatment can shrink tumors and improve surgical outcomes. About 160 adul…

This early-phase study tests whether adding Tumor Treating Fields (TTFields) to standard chemoradiation and immunotherapy is safe for people with stage III lung cancer that cannot be removed by surgery. About 30 participants will receive TTFields alongside their usual treatment. …

This study tests whether adding a nitroglycerin patch (a heart medication) to standard radiation therapy can better shrink brain tumors in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. About 74 adults will receiv…

This study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug shrinks tumors. About 251 participants will receive the dr…

This study tests a new drug (ES102) combined with an immunotherapy (toripalimab) in 40 adults with advanced non-small cell lung cancer that has not responded to prior treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study tests whether using MRI scans to guide radiation therapy, along with chemotherapy and immunotherapy, can reduce side effects and improve outcomes for people with locally advanced non-small cell lung cancer. About 490 participants will be randomly assigned to receive ei…

This study tests whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose cancer has worsened after prior immunotherapy. About 536 adults aged 18–75 with good daily function will be randomly …

This early-stage trial tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a marker called NY-ESO-1. The study includes people with advanced cancers like sarcoma, melanoma, breast, lung, bladder, and ova…

This study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…

This early-stage study is testing a new drug, AOH1996, in adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and understand side effects. The drug works by blocking certai…

This study tests a new experimental drug, BNT116, for people with advanced non-small cell lung cancer. The goal is to find safe doses when given alone or with other cancer treatments. About 320 participants will take part in this early-phase trial.

This study tests whether a new targeted pill (MK-1084) combined with an immunotherapy (pembrolizumab) can help people with a specific KRAS-mutated advanced lung cancer live longer without their cancer growing, compared to standard chemo plus immunotherapy. About 675 adults with n…

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

This phase 3 study tests whether adding the diabetes drug metformin to standard targeted therapy (tyrosine kinase inhibitors) can help control advanced non-small cell lung cancer with EGFR mutations. About 312 adults with stage IIIB or IV lung cancer will receive either metformin…

This study is for adults with early-stage non-small cell lung cancer who are scheduled for surgery. Researchers want to see if adding a third drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink tumors more before surgery and keeps cancer away longer. Abo…

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in people with non-small cell lung cancer that has spread to the brain and has not been treated yet. The goal is to see if the treatment shrinks brain tumors. About 46 adults wi…

This study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive …

This study tests a new drug called MCLA-129 in people with advanced solid tumors like lung, head and neck, or colorectal cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met) to b…

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This study looks at how well the drug pembrolizumab (with or without chemotherapy) works in Black patients with advanced non-small cell lung cancer. About 318 participants will be followed to see how long they live or how long the cancer stays under control. The goal is to find m…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This study looks at whether giving radiation to the chest after surgery can help people with stage III lung cancer who still have some cancer left after chemo and immunotherapy. About 118 adults will be randomly assigned to get either standard follow-up care or additional radiati…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that have stopped responding to standard therapies. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participant…

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This study tests whether removing extra safety margins in adaptive stereotactic radiotherapy can lower the risk of breathing problems for people with early-stage non-small cell lung cancer or limited lung metastases. About 130 participants will be randomly assigned to standard or…

This study is testing a new drug combination (YL201 and ivonescimab) in people with advanced solid tumors, including certain lung cancers. The goal is to see if the combination is safe and can shrink tumors. About 260 adults will take part, and the study is currently recruiting.

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This study tests adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy for people with advanced non-squamous non-small cell lung cancer whose PDL1 is below 50%. The trial has two parts: first, finding the safest dose, then comparing the new combin…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests an experimental drug called sunvozertinib against a placebo in people with a specific type of lung cancer (non-small cell) that has certain gene changes (EGFR exon20 insertion or PACC mutations). Participants must have had their tumor completely removed by surger…

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. About 18 adults with stage IIIB or IV cancer who haven't had prior treatment will take pyrotinib pills. The goal is to se…

This study tests a new drug called ivonescimab against the current standard treatment, pembrolizumab (Keytruda), for people with advanced lung cancer that has spread. It includes 780 adults whose tumors have high levels of a protein called PD-L1. The goal is to see if ivonescimab…

This study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) as a first treatment for people with advanced non-small cell lung cancer that has certain rare gene changes (EGFR PACC mutations). About 480 participants worldwide will be random…

This study tests whether adding the drug envafolimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with stage III non-small cell lung cancer that can be surgically removed. About 390 adults will receive either the combination or a placebo plu…

This study is for people with a type of lung cancer that has spread to a few other places in the body and has specific gene changes. Participants will either continue taking their targeted therapy pills alone or also receive radiation to the cancer spots. The goal is to see if ad…

This early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…

This study tests whether adding chemotherapy to standard immunotherapy (pembrolizumab) can improve outcomes for people with advanced lung cancer. Researchers will use a blood test that detects cancer DNA (ctDNA) to decide when to add chemo. About 230 participants will be enrolled…

This study tests a new drug, HMBD-501, in people with advanced cancers (melanoma, lung, or breast) that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 180 adults will take part in two phases: first to check s…

This study tests whether adding an experimental drug (Dato-DXd) to a standard targeted therapy (osimertinib) helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 582 adults with stage IIIB/IV non-small cell lung cancer will receive ei…

This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study is for people with non-small cell lung cancer that has spread to the brain (1 to 10 spots). Researchers want to see if using MRI-guided radiation without the usual extra safety margins can still be effective while lowering the risk of brain tissue damage. About 168 adu…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that got worse after immunotherapy. About 630 adults will be randomly assigned to receive either the new drug or chemo every three…

This study tests a new drug, NVL-655, against the current standard treatment alectinib for people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if NVL-655 can delay cancer growth or death longer than alectinib. About 45…

This study tests whether adding BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 adults will receive the combination and b…

This study tests a combination of one chemotherapy drug and the immunotherapy pembrolizumab for people with advanced non-small cell lung cancer who have a lower performance status (ECOG PS 2), meaning they need to rest up to half the day. The goal is to see if this treatment is s…

This study tests a new drug called ivonescimab combined with standard chemotherapy and precise radiation (SRS) for people with non-small cell lung cancer that has spread to the brain. The goal is to find a safe dose and see if it helps control the brain tumors. About 53 adults wi…

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…

This study is testing an experimental drug called DRP-104 for people with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2 or KEAP1) and has stopped responding to standard chemotherapy and immunotherapy. The main goal is to see if the drug can shrink …

This is an early-stage study testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack can…

This early-phase study tests a new radioactive tracer for PET scans that may help doctors see non-small cell lung cancer that has spread to the brain more clearly. About 20 adults with this type of cancer will receive the tracer and have a PET/CT scan. The goal is to see if this …

This early study is testing a new imaging agent called FL-261 to see if it can safely and accurately detect and stage several types of cancer, including lung, colorectal, and head & neck cancers. The agent targets a protein (c-MET) found on many cancer cells but not on most healt…

This study is testing a new imaging agent called 18F-T2, which targets a protein (CAIX) found on many solid tumors. About 200 adults with cancers like kidney, bladder, colorectal, or lung cancer will receive a PET/CT scan using this agent. The goal is to see if it can find tumors…

This early-phase trial is testing a special PET imaging agent that targets a protein called IFN-gamma to see if it can find lung cancer tumors and show how well they respond to immunotherapy. Six adults with untreated non-small cell lung cancer will get a PET scan before starting…

This study tests if a special PET scan (FAPI-PET) and a fluorescent dye can help doctors find leftover lung cancer during surgery after standard treatment. About 200 people with stage II-IIIB non-small cell lung cancer will get the scan and dye before and during surgery. The goal…

This early-phase study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the drug is safe, how it moves through the body,…

This study is testing a new type of PET scan that uses a special probe (68Ga-TOI-1) to target a protein called CDH3, which is only found on cancer cells. The goal is to see if this scan can more accurately detect and stage lung cancer compared to the standard PET scan. About 80 a…

This study looks at whether a special microscope called CLE can help doctors find non-small cell lung cancer (NSCLC) while doing a biopsy. About 70 people with suspected lung tumors will have the extra imaging during their standard procedure. The goal is to see if CLE can give a …

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study looks at whether an 8-week pulmonary rehabilitation program can help people with advanced non-small cell lung cancer who have trouble breathing and feel tired. Half of the 85 participants will do the rehab program, while the other half will get their usual care. Resear…

This study follows 180 people with early-stage lung cancer to see if a smaller surgery (segmentectomy) leads to less shortness of breath and better quality of life than a larger surgery (lobectomy) in the year after their operation. Participants fill out questionnaires before sur…

This study looks at whether using a smartphone app (Fissios App) along with in-person breathing exercises can reduce complications after lung cancer surgery. About 560 adults scheduled for lung resection will be randomly assigned to either standard in-person physiotherapy or the …

This study tests whether online singing training can reduce symptoms and improve physical function and quality of life in people who had surgery for early-stage lung cancer 6 to 18 months ago. About 100 participants will be randomly assigned to either online singing sessions or u…

This study tests a technique where a dye is injected into the blood to make healthy lung tissue glow green during robotic surgery. The surgeon can then see and remove only the small cancer-containing segment, leaving more healthy lung behind. The goal is to see if this method is …

This study tests a new version of megestrol acetate (a drug used to boost appetite) in people with advanced non-small cell lung cancer who are getting chemoradiotherapy. About 134 participants will receive either the drug or a placebo alongside standard cancer treatment. The goal…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs will take part to see if the program improves quality of life. The goal …

This study looks at whether adding fermented foods (like yogurt, kimchi, and sauerkraut) to the diet can improve quality of life and treatment response in people with rectal or lung cancer. About 54 participants will either eat these foods regularly or follow their usual diet. Re…

This study tests a 12-week home-based coaching program for people who had surgery for early-stage lung cancer. Participants get a fitness tracker, a smartphone app, and coach calls to help them increase their daily steps. The goal is to see if this program improves physical activ…

This study tests whether a mobile app that guides patients and their caregivers through yoga exercises is safe and easy to use. It includes 60 people with lung or esophageal cancer who are getting radiation therapy, plus a family caregiver. The goal is to see if the app is a prac…

This study is testing whether a supervised exercise program is safe and doable for people with lung cancer who are getting radiation and chemotherapy. Ten participants will do breathing exercises, walking or cycling, and light strength training during their treatment. The goal is…

This study tests whether a special immune-boosting nutrition drink can lower the chance of severe throat and esophagus inflammation (esophagitis) in lung cancer patients getting chest radiation. About 121 adults with lung cancer will either receive standard care or the immunonutr…

This study looks at 300 people with early-stage lung cancer to understand why some tumors grow differently. Researchers will analyze genes, immune cells, and other markers from tumor samples. The goal is to find patterns that could lead to better predictions of cancer return and …

This study follows about 500 adults with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) by their doctor. Researchers want to see how well the drug works and how safe it is in everyday medical practice, not just in controlled trials. The main g…

This study tests a new way to predict how well your lungs will work after lung cancer surgery. Doctors use a 3D CT scan to create a virtual model of your lungs and simulate the surgery beforehand. The goal is to improve safety and help plan recovery. About 60 adults with non-smal…

This study aims to find biological signs of aging that can predict how older patients with lung cancer will respond to treatment. Researchers will analyze blood and tissue samples from 385 patients aged 70 and older with early-stage non-small cell lung cancer. The goal is to redu…

This study collects tumor samples, blood, and health information from 2,000 adults with certain lung and thymic cancers. The goal is to better understand these diseases and support future research. Participants do not receive treatment as part of this study.

This study is collecting blood and tumor samples from 1100 people with various cancers (like head and neck, ovarian, and lung cancer) to learn how immune cells called T cells behave. The goal is to understand why some cancers are better at hiding from the immune system. Participa…

This study is testing a new, non-invasive technology called an electronic nose (E-nose) that analyzes chemicals in a person's breath. Researchers want to see if these breath 'fingerprints' can accurately show how well lung cancer responds to treatment and if the cancer comes back…

This study uses a survey to find out what Chinese patients and doctors consider most important when choosing a first-line targeted therapy for advanced non-small cell lung cancer. About 590 participants (patients and physicians) will answer questions about treatment preferences, …

This study is observing 50 adults with advanced cancers (like lung, breast, or colon) who are starting immunotherapy. Researchers want to see if changes in a blood marker called ctDNA can predict early on whether the treatment is working. They will also look at other tumor marker…

This study follows 500 adults aged 70 and older who are starting their first treatment for non-small cell lung cancer. Researchers will collect information on how well the treatments work, side effects, and quality of life. The goal is to learn more about what happens in everyday…

This study looks at why some lung cancers with a specific gene change (EGFR exon 20 insertion) stop responding to the drug amivantamab. Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find the genetic changes that ca…

This study examines the genetic changes in early-stage lung cancer that comes back after treatment with the drug osimertinib. Researchers will analyze tumor or blood samples from 60 adults whose cancer has returned. The goal is to better understand why recurrence happens, not to …

This study is for people with non-small cell lung cancer who have had or will have surgery to remove their tumor. Researchers will collect blood samples and health information over time to see how the cancer changes and whether a simple blood test can predict if the cancer will c…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…

This study is for people with advanced colorectal or non-small cell lung cancer. It tests whether adding a special blood test (ctDNA) to regular scans helps doctors choose the best treatment. About 332 participants will be randomly assigned to either standard care or the extra bl…

This study tests whether urolithin A, a natural compound, can improve how the immune system responds to standard immunotherapy in people with solid tumors like lung cancer or melanoma. About 45 participants who have not had prior cancer treatment will receive either urolithin A o…

This study is not testing a new drug but watching how well standard treatments work for people with a specific type of lung cancer (EGFR-mutated NSCLC) in everyday medical practice. About 538 adults with advanced lung cancer will be followed to see how long they live without the …

This study watches 100 adults with a certain type of advanced lung cancer who are already receiving a drug combo (amivantamab plus chemo) through an early access program. Researchers want to see how long the treatment keeps the cancer from growing in everyday medical practice. No…

This study looks at why some lung cancer cells survive targeted treatment. Researchers will take small tissue samples (biopsies) before and two weeks after starting therapy to spot early signs of resistance. The goal is to find ways to block these survival pathways and make treat…

This study collects samples from 320 people, including those with solid cancers and those undergoing lung cancer screening, to detect tumor cells and DNA in blood, urine, and bone marrow. The goal is to learn more about how cancer spreads and to improve early detection and person…

This study is gathering information from 130 people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) who are starting a standard treatment called osimertinib. The goal is to see how long the treatment keeps the cancer from growing in everyday …

This study collects information from 550 people with advanced lung cancer who are receiving standard treatments. The goal is to create a 'control arm' using real-world data instead of a placebo group. This could help future trials compare new treatments more quickly and accuratel…

This study is testing whether a new, simple method of collecting rectal mucus can find DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic mark…

This study aims to learn more about the biological features of a specific type of lung cancer called ALK-positive non-small cell lung cancer. Researchers will collect tumor tissue and blood samples from 100 patients to analyze how the cancer changes over time and why it may stop …

This study looks at whether the type of anesthesia given during lung cancer surgery can influence whether the cancer comes back. About 5,384 people having surgery to remove non-small cell lung cancer will be randomly assigned to receive either inhaled gas anesthesia or intravenou…

This study uses machine learning (a type of artificial intelligence) to analyze data from over 144,000 patients with advanced non-small cell lung cancer. The goal is to find which existing treatments work best for different types of patients, rather than testing a new drug. The r…

This study aims to understand lung cancer better in people diagnosed at age 45 or younger. Researchers will collect blood and tumor samples from 500 participants to look for genetic changes and other markers. The goal is to find new ways to treat or detect this disease earlier.

This study looks at whether a lab-made model of a patient's lung cancer tumor can help doctors choose the best drugs. Researchers will grow tumor-like cell clusters from patient samples and test which medicines work best. The goal is to see if these lab results match real patient…

This study enrolls 620 adults with solid cancers (lung, esophageal, stomach, pancreatic, liver, colorectal) to collect blood, urine, and bone marrow samples. Researchers will measure circulating tumor cells and DNA to see how they relate to cancer recurrence and survival. The goa…

This study is measuring a protein called Galectin-3 in the blood of 300 people with kidney, bladder, lung, or liver cancer who are starting immunotherapy. The goal is to see if higher levels of this protein are linked to worse treatment outcomes or more side effects. Researchers …

This study aims to understand cancer-related fatigue in 20 adults with non-small cell lung cancer who are receiving immunotherapy. Researchers will conduct interviews and use questionnaires to learn about fatigue patterns, daily life impacts, and patients' views on physical activ…

This study looks at using a precise type of radiation (SBRT) again in lung cancer patients whose cancer came back in the same spot after previous radiation. It includes 150 patients who cannot have surgery. The goal is to learn how safe and effective this second treatment is, sin…

This observational study aims to understand why some people with a specific type of lung cancer (ROS1-positive NSCLC) stop responding to the targeted drug entrectinib. Researchers will analyze tumor or blood samples from 38 participants who have already taken entrectinib as part …

This study aims to collect and analyze tumor tissue from 550 people with advanced non-small-cell lung cancer in Taiwan. The goal is to create a detailed map of genetic changes that drive the cancer, especially in patients whose tumors do not respond to standard targeted therapies…

This study observes about 500 Spanish adults with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) who are taking the drug osimertinib in everyday medical practice. Researchers will track how long patients live, how well the drug controls the cancer, and t…

This study looks at the variety of bacteria in the gut of people with advanced non-small cell lung cancer. Researchers want to see if the types of gut bacteria are linked to how well treatment works or what side effects occur. About 82 participants will provide stool samples befo…

This study looks at whether measuring the amount of pembrolizumab in the blood can help predict how well it works and what side effects occur in people with non-small cell lung cancer. About 75 adults already receiving pembrolizumab will have their drug levels checked and linked …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why they respond differently to treatments. The goal is to develop more effective therapi…